SciClone Pharmaceuticals Inc (SCLN)

The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 528,413 share decrease in total short interest for SciClone Pharmaceuticals, Inc. , to 1,960,649, a decrease of 21.23% since 07/15/2016.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Investors in SciClone Pharmaceuticals, Inc. saw new options begin trading this week, for the August 19th expiration.

Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a weak on high relative volume candidate

Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a weak on high relative volume candidate

Oil controls the market, and Cramer is watching stocks to see which you should be buying.

Cramer is no fan of J.C. Penney and says NCR is up too much.

Investors in SciClone Pharmaceuticals, Inc. saw new options become available this week, for the May 20th expiration.

Investors considering a purchase of SciClone Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $9.74/share, might benefit from considering selling puts among the alternative strategies at their disposal.

In trading on Friday, shares of SciClone Pharmaceuticals, Inc. crossed above their 200 day moving average of $8.58, changing hands as high as $8.93 per share.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Stocks with insider trader activity include MW, SCLN and ATHN

Investors considering a purchase of SciClone Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $10.01/share, might benefit from considering selling puts among the alternative strategies at their disposal.

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADT, AIN, BDBD, CBS.A, CRAY, EGT, FPRX, GERN, HMPR, ISIL, SCLN Downgrades: ASM, BRS, SRDX Initiations: DPLO, W Read on to get TheStreet Quant Ratings' detailed report:

Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a strong on high relative volume candidate

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a strong on high relative volume candidate

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Investors considering a purchase of SciClone Pharmaceuticals, Inc. shares, but cautious about paying the going market price of $8.50/share, might benefit from considering selling puts among the alternative strategies at their disposal.

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BECN, EGT, EMKR, LDR, PAR Downgrades: CIA, CJJD, CNP, ENDP, EVTC, FLR, FPRX, FRED, NTAP, OLED, SCLN, SLAB, XON, ZGNX Initiations: LMCK, LPG Read on to get TheStreet Quant Ratings' detailed report:

Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a weak on high relative volume candidate

Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a weak on high relative volume candidate

Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a strong on high relative volume candidate

Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a strong on high relative volume candidate

Looking to add even more performance to your portfolio? Consider pharmaceutical stocks with so-called high beta - a common measurement of volatility.

Stocks with insider trader activity include SANW, STRZA and SCLN

Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a strong on high relative volume candidate